<DOC>
	<DOCNO>NCT00390221</DOCNO>
	<brief_summary>The primary objective study determine whether DAC HYP , compare placebo , effective reduce rate relapse baseline Week 52 . The secondary objective determine whether DAC HYP effective reduce number new gadolinium ( Gd ) -enhancing lesion , reduce number new newly-enlarging T2 hyperintense lesion , reduce proportion participant relapse , improve quality life .</brief_summary>
	<brief_title>Safety Efficacy Study Daclizumab High Yield Process ( DAC HYP ) Treat Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Key Multiple Sclerosis ( MS ) subject confirm diagnosis relapsingremitting MS accord McDonald criterion # 14 baseline Expanded Disability Status Scale ( EDSS ) 0.0 5.0 , inclusive , meet either follow 2 criterion : Have experience least 1 relapse within 12 month prior randomization , cranial magnetic resonance imaging ( MRI ) demonstrate lesion ( ) consistent MS , OR Show evidence gadoliniumenhancing lesion brain MRI perform within 6 week prior randomization . Key Diagnosis primary progressive , secondary progressive , progressive relapse MS History malignancy History severe allergic anaphylactic reaction know drug hypersensitivity History abnormal laboratory result base investigator judgment History human immunodeficiency virus ( HIV ) immunodeficient condition History drug alcohol abuse within 2 year prior randomization An MS relapse occur within 50 day prior randomization AND/OR subject stabilize previous relapse prior randomization Positive screen active infection Hepatitis B virus Hepatitis C virus Varicella herpes zoster virus infection severe viral infection within 6 week Screening Exposure varicella zoster virus within 21 day Screening . Abnormal blood test Screening : Hemoglobin ≤9.0 g/dL , Platelets ≤100 × 10^9/L , Lymphocytes ≤1.0 × 10^9/L , Neutrophils ≤1.5 × 10^9/L , alanine aminotransferase/serum glutamate pyruvate transaminase ( ALT/SGPT ) , aspartate aminotransferase/serum glutamic oxaloacetic transaminase ( AST/SGOT ) , gammaglutamyltransferase &gt; 2 time upper limit normal ( ULN ) serum creatinine &gt; ULN . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>MS</keyword>
	<keyword>multiple sclerosis</keyword>
</DOC>